BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 16513619)

  • 1. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
    Yang YS; Zhang X; Xiong Z; Chen X
    Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
    Li ZB; Wu Z; Chen K; Ryu EK; Chen X
    J Nucl Med; 2008 Mar; 49(3):453-61. PubMed ID: 18287274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
    J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
    Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
    Faintuch BL; Teodoro R; Duatti A; Muramoto E; Faintuch S; Smith CJ
    Nucl Med Biol; 2008 May; 35(4):401-11. PubMed ID: 18482677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
    García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
    Ferro-Flores G; Arteaga de Murphy C; Rodriguez-Cortés J; Pedraza-López M; Ramírez-Iglesias MT
    Nucl Med Commun; 2006 Apr; 27(4):371-6. PubMed ID: 16531924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
    Liu Z; Yan Y; Liu S; Wang F; Chen X
    Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
    Okarvi SM; Al Jammaz I
    Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
    Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS
    Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.